5-alpha-reductase Inhibitors
2 drugsAbout 5-alpha-reductase
5-alpha-reductase is an enzyme that converts testosterone to dihydrotestosterone (DHT), a more potent androgen. DHT plays a key role in male characteristic development and maintenance. Overproduction of DHT can contribute to conditions addressed by current medications.
While there is no genetic evidence directly linking 5-alpha-reductase to specific diseases, its role in androgen metabolism makes it a therapeutic target. Inhibiting 5-alpha-reductase can reduce DHT levels, addressing related conditions.
Two drugs targeting 5-alpha-reductase are FDA-approved: JALYN and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE. Both are small molecule drugs and are used in 'other' therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bladder Cancer with only 1 trials.
Top 5-alpha-reductase Drugs
WAYLIS THERAP and Aurobindo Pharma are the companies with approved drugs targeting this enzyme.
The market is unconcentrated, suggesting relatively low barriers to entry for new competitors.
5-alpha-reductase Drug Modality Landscape
Modalities
Routes of Administration
5-alpha-reductase is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies could provide a competitive advantage.
5-alpha-reductase Clinical Trials 110 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 25 | 21 | 2 | 2 | 91% |
| Phase 2 | 26 | 14 | 5 | 7 | 74% |
| Phase 3 | 25 | 13 | 7 | 5 | 65% |
| Phase 4 | 34 | 25 | 6 | 3 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-alpha-reductase Drug Approval Timeline (2010 - 2014)
The first drug was approved in 2010 (JALYN), and the most recent in 2014 (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE).
The approval timeline suggests a potential slowdown or saturation in this therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 59 clinical trials targeting 5-alpha-reductase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities